NOVOLIN GE 30/70 SUSPENSION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

INSULIN INJECTION HUMAN BIOSYNTHETIC; INSULIN ISOPHANE HUMAN BIOSYNTHETIC

Disponible des:

NOVO NORDISK CANADA INC

Codi ATC:

A10AD01

Designació comuna internacional (DCI):

INSULIN (HUMAN)

Dosis:

30UNIT; 70UNIT

formulario farmacéutico:

SUSPENSION

Composición:

INSULIN INJECTION HUMAN BIOSYNTHETIC 30UNIT; INSULIN ISOPHANE HUMAN BIOSYNTHETIC 70UNIT

Vía de administración:

SUBCUTANEOUS

Unidades en paquete:

10ML

tipo de receta:

Schedule D

Área terapéutica:

INSULINS

Resumen del producto:

Active ingredient group (AIG) number: 0223312003; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2011-01-07

Fitxa tècnica

_ _
_Novolin_
_®_
_ge_
_ – _
_Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 52 _
_ _
PRODUCT MONOGRAPH
Schedule D
NOVOLIN
®
GE
Insulin, Human Biosynthetic
Injectable Solution/Suspension
Manufacturer’s Standard
Antidiabetic Agent
Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1
DATE OF INITIAL APPROVAL:
January 7, 2011
CONTROL NO.: 227125
DATE OF REVISION: July 26, 2019
_ _
_Novolin_
_®_
_ge_
_ – _
_Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 52 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 3
SUMMARY PRODUCT
INFORMATION.................................................................................
3
DESCRIPTION
............................................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................................
5
ADVERSE REACTIONS
............................................................................................................
8
DRUG INTERACTIONS
..........................................................................................................
10
DOSAGE AND ADMINISTRATION
......................................................................................
11
OVERDOSAGE
.........................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
15
STORAGE AND STABILITY
..................................................................................................
16
SPECIAL HANDLING INSTRUCTIONS
...........................